OccuLogix Appoints Adrienne L. Graves, Ph.D. To Its Board Of Directors

TORONTO--(BUSINESS WIRE)--May 2, 2005--OccuLogix, Inc. (NASDAQ:RHEO)(TSX:RHE) announced today that Adrienne L. Graves, Ph.D. has been appointed to its Board of Directors. Since 2002, Dr. Graves has been President and CEO of Santen Inc., a wholly owned subsidiary of Japan's Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4536). She joined Santen Inc. in 1995 as Vice President of Clinical Affairs to initiate the company's clinical development in the U.S. Under her leadership, Santen's research and development team successfully developed and obtained U.S. Food and Drug Administration ("FDA") approval for three ophthalmic products in major therapeutic areas. Santen's U.S. products are now marketed by Johnson & Johnson Vision Care.

Back to news